PSI CRO has chosen goBalto’s end-to-end study startup platform for conducting clinical trials from site identification, feasibility and selection through to site activation.
PSI CRO has chosen goBalto’s end-to-end study startup platform for conducting clinical trials from site identification, feasibility and selection through to site activation. PSI CRO will apply the platform for use in a multi-country Phase II Infectious Disease Study.
Read the full release here
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.